Celcuity IncNASDAQ:CELC
- LAST PRICE12.8500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.1700/ 1
- Ask / Lots20.3200/ 4
- Open / Previous Close--- / 12.8500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELC |
|---|---|---|
| 09:32 ET | 5081 | 13.24 |
| 09:33 ET | 100 | 13.12 |
| 09:35 ET | 3370 | 13.02 |
| 09:37 ET | 1870 | 12.81 |
| 09:39 ET | 100 | 12.78 |
| 09:42 ET | 300 | 12.88 |
| 09:44 ET | 300 | 12.88 |
| 09:46 ET | 354 | 12.935 |
| 09:50 ET | 200 | 13.005 |
| 09:51 ET | 414 | 13 |
| 09:55 ET | 174 | 12.995 |
| 10:02 ET | 100 | 12.935 |
| 10:04 ET | 200 | 13 |
| 10:11 ET | 100 | 12.99 |
| 10:13 ET | 323 | 12.97 |
| 10:18 ET | 100 | 12.965 |
| 10:24 ET | 100 | 12.985 |
| 10:26 ET | 1170 | 13.01 |
| 10:27 ET | 200 | 12.95 |
| 10:29 ET | 100 | 12.96 |
| 10:33 ET | 100 | 13 |
| 10:36 ET | 141 | 13.001 |
| 10:40 ET | 189 | 12.96 |
| 10:44 ET | 200 | 12.965 |
| 10:45 ET | 554 | 13.04 |
| 10:56 ET | 202 | 13.025 |
| 10:58 ET | 142 | 13.025 |
| 11:00 ET | 200 | 13.015 |
| 11:03 ET | 100 | 13.005 |
| 11:05 ET | 747 | 13.01 |
| 11:07 ET | 1300 | 13.01 |
| 11:09 ET | 3200 | 13 |
| 11:12 ET | 500 | 13.05 |
| 11:14 ET | 1966 | 13.01 |
| 11:16 ET | 1075 | 12.98 |
| 11:20 ET | 100 | 13 |
| 11:25 ET | 110 | 13 |
| 11:30 ET | 200 | 12.98 |
| 11:34 ET | 644 | 12.98 |
| 11:36 ET | 1092 | 13.04 |
| 11:38 ET | 1100 | 13.01 |
| 11:39 ET | 1000 | 13.01 |
| 11:41 ET | 801 | 13.01 |
| 11:43 ET | 1100 | 13.01 |
| 11:45 ET | 500 | 13.04 |
| 11:48 ET | 2653 | 13.01 |
| 11:50 ET | 100 | 12.99 |
| 11:52 ET | 1613 | 13.02 |
| 11:54 ET | 300 | 13.02 |
| 11:56 ET | 500 | 13 |
| 11:57 ET | 115 | 13.005 |
| 11:59 ET | 305 | 12.98 |
| 12:01 ET | 123 | 12.98 |
| 12:03 ET | 585 | 12.95 |
| 12:06 ET | 100 | 12.98 |
| 12:10 ET | 100 | 12.95 |
| 12:12 ET | 800 | 12.975 |
| 12:14 ET | 558 | 12.975 |
| 12:15 ET | 534 | 13.02 |
| 12:17 ET | 1464 | 13 |
| 12:19 ET | 200 | 12.99 |
| 12:21 ET | 100 | 13.025 |
| 12:24 ET | 100 | 13 |
| 12:26 ET | 100 | 13.02 |
| 12:28 ET | 100 | 12.98 |
| 12:30 ET | 100 | 12.975 |
| 12:33 ET | 100 | 12.955 |
| 12:35 ET | 100 | 12.96 |
| 12:37 ET | 200 | 12.945 |
| 12:39 ET | 2589 | 12.97 |
| 12:42 ET | 129 | 12.97 |
| 12:44 ET | 318 | 12.955 |
| 12:48 ET | 600 | 12.945 |
| 12:50 ET | 579 | 12.96 |
| 12:53 ET | 4296 | 12.95 |
| 12:55 ET | 7419 | 12.92 |
| 12:57 ET | 700 | 12.9 |
| 01:00 ET | 233 | 12.935 |
| 01:02 ET | 200 | 12.935 |
| 01:04 ET | 568 | 12.94 |
| 01:06 ET | 1465 | 12.93 |
| 01:08 ET | 100 | 12.925 |
| 01:09 ET | 100 | 12.925 |
| 01:11 ET | 201 | 12.92 |
| 01:13 ET | 100 | 12.925 |
| 01:15 ET | 2579 | 12.915 |
| 01:18 ET | 940 | 12.9 |
| 01:22 ET | 200 | 12.905 |
| 01:24 ET | 200 | 12.91 |
| 01:26 ET | 786 | 12.89 |
| 01:27 ET | 404 | 12.91 |
| 01:29 ET | 100 | 12.91 |
| 01:31 ET | 200 | 12.9 |
| 01:36 ET | 100 | 12.9 |
| 01:38 ET | 500 | 12.905 |
| 01:42 ET | 800 | 12.9015 |
| 01:44 ET | 714 | 12.915 |
| 01:45 ET | 606 | 12.9 |
| 01:51 ET | 100 | 12.92 |
| 01:54 ET | 609 | 12.902 |
| 01:56 ET | 100 | 12.92 |
| 01:58 ET | 500 | 12.91 |
| 02:00 ET | 400 | 12.91 |
| 02:02 ET | 280 | 12.91 |
| 02:05 ET | 100 | 12.905 |
| 02:07 ET | 200 | 12.9 |
| 02:12 ET | 4212 | 12.8909 |
| 02:14 ET | 348 | 12.9 |
| 02:16 ET | 100 | 12.88 |
| 02:20 ET | 627 | 12.88 |
| 02:21 ET | 3558 | 12.94 |
| 02:23 ET | 3100 | 12.96 |
| 02:25 ET | 184 | 12.99 |
| 02:27 ET | 2356 | 12.91 |
| 02:30 ET | 100 | 12.95 |
| 02:32 ET | 200 | 12.94 |
| 02:34 ET | 1001 | 12.93 |
| 02:36 ET | 200 | 12.93 |
| 02:38 ET | 600 | 12.9 |
| 02:39 ET | 1435 | 12.95 |
| 02:41 ET | 300 | 12.96 |
| 02:43 ET | 700 | 12.9325 |
| 02:48 ET | 400 | 12.96 |
| 02:50 ET | 4500 | 13.01 |
| 02:52 ET | 283 | 13.055 |
| 02:54 ET | 1554 | 13.08 |
| 02:56 ET | 1110 | 13.07 |
| 02:59 ET | 100 | 13.02 |
| 03:01 ET | 100 | 13.02 |
| 03:03 ET | 100 | 13 |
| 03:06 ET | 300 | 12.98 |
| 03:08 ET | 23184 | 12.88 |
| 03:10 ET | 12951 | 12.875 |
| 03:12 ET | 1893 | 12.88 |
| 03:14 ET | 200 | 12.87 |
| 03:21 ET | 300 | 12.87 |
| 03:26 ET | 100 | 12.87 |
| 03:28 ET | 1803 | 12.9 |
| 03:30 ET | 200 | 12.9 |
| 03:32 ET | 11595 | 12.9 |
| 03:33 ET | 1796 | 12.885 |
| 03:35 ET | 2063 | 12.885 |
| 03:37 ET | 822 | 12.855 |
| 03:39 ET | 100 | 12.87 |
| 03:42 ET | 200 | 12.88 |
| 03:44 ET | 100 | 12.89 |
| 03:46 ET | 884 | 12.87 |
| 03:48 ET | 100 | 12.9 |
| 03:50 ET | 800 | 12.88 |
| 03:51 ET | 1700 | 12.88 |
| 03:53 ET | 4064 | 12.83 |
| 03:55 ET | 2400 | 12.83 |
| 03:57 ET | 5110 | 12.84 |
| 04:00 ET | 33034 | 12.85 |
Nov 15, 2024
DJ Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co., from 2:38PM ET on Friday Nov 15, 2024 by Dow Jones
2:38PM ET on Friday Nov 15, 2024 by Dow JonesDJ Celcuity Down Over 12%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk, from 1:42PM ET on Friday Nov 15, 2024 by Dow Jones
1:42PM ET on Friday Nov 15, 2024 by Dow JonesDJ Celcuity Price Target Maintained With a $23.00/Share by Needham, from 5:16AM ET on Friday Nov 15, 2024 by Dow Jones
5:16AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Press Release: Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow JonesCelcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celcuity Inc | 477.1M | -4.9x | --- |
GH Research PLC | 482.8M | 0.0x | --- |
ACELYRIN Inc | 465.5M | -1.7x | --- |
Kalvista Pharmaceuticals Inc | 495.2M | -2.9x | --- |
Terns Pharmaceuticals Inc | 499.4M | -5.4x | --- |
Aura Biosciences Inc | 449.6M | -5.2x | --- |
Company Information
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Contact Information
- Headquarters
- 16305 36th Ave N Ste 100MINNEAPOLIS, MN, United States 55446-4285
- Phone
- 763-392-0767
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Brian Sullivan
- Co-Founder, Chief Science Officer, Vice President, Secretary, Director
- Lance Laing
- Chief Financial Officer
- Vicky Hahne
- Chief Commercial Officer
- Eldon Mayer
- Independent Director
- Richard Buller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $477.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-2.61 |
Book Value | $5.48 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
